Literature DB >> 25739966

Interest of repetitive transcranial magnetic stimulation of the motor cortex in the management of refractory cancer pain in palliative care: Two case reports.

Julien Nizard1, Amélie Levesque2, Nathalie Denis2, Edwige de Chauvigny2, Aurélie Lepeintre2, Sylvie Raoul3, Jean-Jacques Labat2, Samuel Bulteau4, Benoît Maillard2, Kevin Buffenoir3, Gilles Potel2, Jean-Pascal Lefaucheur5, Jean Paul Nguyen3.   

Abstract

BACKGROUND: Non-drug treatments should be systematically associated to the medical analgesic treatment during the terminal phase of cancer. CASES
PRESENTATION: Patient 1, a 23-year-old woman, presented an adenocarcinoma of the rectum, with liver and lung metastases. Pain was initially treated by oral morphine and a combination of pregabalin and amitriptyline. Ketamine and intrathecal administration of morphine were both ineffective. Patient 2, a 69-year-old woman, presented a cutaneous T-cell lymphoma. She was admitted to the palliative care unit with mixed pain related to cutaneous lymphomatous infiltration. World Health Organization (WHO) step 3 analgesics had not been tolerated. CASES MANAGEMENT: Both patients received five consecutive 20-min sessions of repetitive transcranial magnetic stimulation to the right motor cortex. CASES OUTCOME: Patient 1 experienced a marked improvement of her pain over the days following the first repetitive transcranial magnetic stimulation session. Medical treatment was able to be rapidly decreased by about 50%, which restored an almost normal level of consciousness and lucidity. Patient 2's pain was also markedly decreased over the days following these five consecutive sessions, and repetitive transcranial magnetic stimulation also appeared to have had a beneficial effect on the patient's anxiety and mood.
CONCLUSION: In the context of palliative care of cancer patients experiencing refractory pain that is difficult to control by the usual treatments, motor cortex repetitive transcranial magnetic stimulation, due to its noninvasive nature, can be used as an adjuvant therapy to improve various components of pain, including the emotional components. By reducing the doses of analgesics, repetitive transcranial magnetic stimulation decreases the severity of their adverse effects and improves the patient's quality of life.
© The Author(s) 2015.

Entities:  

Keywords:  Refractory pain; cancer pain; quality of life; rTMS; repetitive transcranial magnetic stimulation

Mesh:

Year:  2015        PMID: 25739966     DOI: 10.1177/0269216315574260

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  5 in total

Review 1.  Analgesic Effect of Noninvasive Brain Stimulation for Neuropathic Pain Patients: A Systematic Review.

Authors:  Kun-Long Zhang; Hua Yuan; Fei-Fei Wu; Xue-Yin Pu; Bo-Zhi Liu; Ze Li; Kai-Feng Li; Hui Liu; Yi Yang; Ya-Yun Wang
Journal:  Pain Ther       Date:  2021-03-22

Review 2.  Recent advances in understanding and managing cancer pain.

Authors:  Marcin Chwistek
Journal:  F1000Res       Date:  2017-06-20

3.  Repetitive Transcranial Magnetic Stimulation as a Promising Potential Therapeutic Modality for the Management of Cancer-related Pain: An Issue that Merits Further Research.

Authors:  Amir Emami Zeydi; Ravanbakhsh Esmaeili; Farshad Hasanzadeh Kiabi; Hassan Sharifi
Journal:  Indian J Palliat Care       Date:  2017 Jan-Mar

4.  Successful treatment of refractory cancer pain with morphine and ropivacaine: A case report.

Authors:  Hongyan Li; Liqiang Yang; Zhaoxuan Guo; Yuanzhang Tang; Nan Chen; Yinying Lu; Jiaxiang Ni
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

5.  A multicentre survey of pain management in cancer patients and physicians attending radiotherapy clinics in Shandong Province, China.

Authors:  Bingxu Tan; Baosheng Li; Yongheng An; Xuezhen Ma; Yuhua Jiang; Yipeng Song; Xingping Ge; Shengli Yuan; Liping Liu; Yan Dou; Yanxia Yu; Pu Ji; Xia Li; Yufeng Cheng
Journal:  J Int Med Res       Date:  2019-10-06       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.